NASDAQ:FLXN Flexion Therapeutics (FLXN) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free FLXN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$9.12▼$9.1250-Day Range$9.12▼$9.4452-Week Range$4.30▼$13.66VolumeN/AAverage Volume1.18 million shsMarket Capitalization$458.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Flexion Therapeutics alerts: Email Address Ad DTIIf you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! Click here to unlock the Income Glitch training workshop for free. About Flexion Therapeutics Stock (NASDAQ:FLXN)Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.Read More Ad DTIIf you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! Click here to unlock the Income Glitch training workshop for free. FLXN Stock News HeadlinesApril 25, 2024 | finance.yahoo.comFlexion wins contract to support CFPB in evaluating financial education contentApril 19, 2024 | finance.yahoo.comFlexion awarded contract to revolutionize Head Start’s Data Management SystemApril 27, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.April 11, 2024 | tmcnet.comFlexion Joins AWS Public Sector Partner Program, Enhancing Commitment to Public Sector Software ProjectsApril 6, 2024 | seekingalpha.comVIRI Virios Therapeutics, Inc.February 14, 2024 | morningstar.comSpyre Therapeutics Inc SYREFebruary 10, 2024 | benzinga.comPFIZER INC's Net WorthNovember 24, 2023 | benzinga.comSpringWorks Therapeutics Stock (NASDAQ:SWTX), Analyst Ratings, Price Targets, PredictionsApril 27, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.July 11, 2023 | benzinga.comFlexion wins MCADS contract to modernize CMS Claims Handling SystemJuly 10, 2023 | finance.yahoo.comFlexion achieves Select Tier Status within the AWS Partner NetworkJune 10, 2023 | yahoo.com7 Exercises to Stretch Plantar Flexion MovementMay 16, 2023 | marketwatch.com2023-2029 Flexion Tires Market Growth Prospects and Countries Analysis | with 91 PagesMay 4, 2023 | finance.yahoo.comOPPO Find N2 Flip's Flexion Hinge Marks A Breakthrough In Flip Phone ExperienceApril 28, 2023 | marketwatch.comProne Leg Flexion Trainers Market Global Outlook and Projection till 2029April 12, 2023 | marketwatch.comAbdominal Flexion Training Device Market Research & Size Analysis 2023-2028April 6, 2023 | marketwatch.comProne Leg Flexion Trainers Market 2023 Huge Demand, Growth Opportunities and Expansion by 2031March 23, 2023 | marketwatch.comGlobal Flexion Tires Market: Future Extrapolations and Emerging Updates for 2023-2027February 24, 2023 | msn.comOppo’s new Flexion hinge has made flip phones more practical and crease minimalSeptember 21, 2022 | seekingalpha.comPCRX Pacira BioSciences, Inc.September 1, 2022 | thestreet.comCoherus BioSciences Inc. NewsAugust 17, 2022 | venturebeat.comFlexion targets TikTok influencers on behalf of game developersJuly 2, 2022 | thestreet.comBiotech Movers: Akebia Soars on Expanded Partnership With OtsukaJanuary 13, 2022 | thestreet.comWhy Flexion Therapeutics (FLXN) Stock Is Plummeting in After-Hours Trading TodayNovember 3, 2021 | finance.yahoo.comPacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss MarkNovember 1, 2021 | finance.yahoo.comSHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing InvestigationsOctober 30, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flexion Therapeutics, Inc. - FLXNSee More Headlines Receive FLXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Flexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/12/2021Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FLXN CUSIPN/A CIK1419600 Webwww.flexiontherapeutics.com Phone(781) 305-7777Fax781-202-3399Employees257Year Founded2007Profitability EPS (Most Recent Fiscal Year)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,710,000.00 Net Margins-100.32% Pretax Margin-100.32% Return on EquityN/A Return on Assets-44.26% Debt Debt-to-Equity RatioN/A Current Ratio4.38 Quick Ratio4.05 Sales & Book Value Annual Sales$85.55 million Price / Sales5.36 Cash FlowN/A Price / Cash FlowN/A Book Value($0.34) per share Price / Book-26.82Miscellaneous Outstanding Shares50,321,000Free Float45,727,000Market Cap$458.93 million OptionableOptionable Beta1.53 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMichael D. ClaymanPresident, Chief Executive Officer & DirectorFred DriscollChief Financial OfficerWilliam T. AndrewsChief Medical OfficerCarolyn Beaty ScimemiChief Compliance Officer & Head-Legal AffairsChristina WillwerthChief Strategy OfficerKey CompetitorsAdlai NortyeNASDAQ:ANLFulcrum TherapeuticsNASDAQ:FULCIGM BiosciencesNASDAQ:IGMSAcelyrinNASDAQ:SLRNShattuck LabsNASDAQ:STTKView All Competitors FLXN Stock Analysis - Frequently Asked Questions How were Flexion Therapeutics' earnings last quarter? Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced its quarterly earnings results on Wednesday, May, 12th. The specialty pharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.08. The specialty pharmaceutical company had revenue of $24.59 million for the quarter, compared to the consensus estimate of $24.61 million. What is Mike Clayman, MD's approval rating as Flexion Therapeutics' CEO? 46 employees have rated Flexion Therapeutics Chief Executive Officer Mike Clayman, MD on Glassdoor.com. Mike Clayman, MD has an approval rating of 85% among the company's employees. What other stocks do shareholders of Flexion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Aduro Biotech (ADRO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Verastem (VSTM). This page (NASDAQ:FLXN) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flexion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
